Followers | 2543 |
Posts | 250734 |
Boards Moderated | 34 |
Alias Born | 05/06/2014 |
Thursday, January 29, 2015 3:02:14 PM
This is what all the hoopla is about. You are looking at a "Chemo Therapy Uber Car". This is a delivery system for cancer therapies.
This capsule is owned and manufactured by PMCB, and it's about the size of the head of a pin. Once fabricated, the capsules can be frozen and stored for over 5 years. Each capsule can hold about 10,000 chemo therapy cells.
The capsules are injected directly into or near a tumor, and the capsule will deliver the treatment directly to the cancer cells over a long period of time. In past studies it has been demonstrated less toxic medication is required for a far better outcome for patients- the Holy Grail of cancer therapy is life extension while minimizing side effects. PMCB delivers this as reliably as UBER delivers passengers.
Dr. Von Hoff Factor
Last May PMCB delivered a major breakthrough. Translational Drug Development of Arizona agreed to conduct preclinical and clinical trials.
The gentleman you see pictured here is the head of Translational Drug- Dr. Daniel Von Hoff. His company has spent the last 2 decades developing cancer drugs. He was on President Bush's National Cancer Society Board, the FDA's oncology Advisory Committee, and is the former President of the American Association for Cancer Research.
Under Von Hoff's direction, the first preliminary studies have been concluded, and the clinical protocol for the Phase 2B trial has been developed. The next step is planning the commencement of the trial with the FDA and other similar agencies Internationally.
On December 22 PMCB announced its Pancreatic Cancer Therapy had received "Orphan Drug Status" from the US FDA- a huge coup. Thanks to the proximity to Christmas, the announcement did not receive proper recognition. To see the evidence on the FDA web site, simply Click Here.
Orphan Drug status is reserved for drugs or treatments for "rare, life threatening diseases." Once approved, PMCB will own the drug exclusively for 7 years.
"Patience, persistence and perspiration make an unbeatable combination for success."
Recent PMCB News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 10:06:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:28 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/04/2023 08:40:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:01:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/31/2023 09:18:17 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM